Trial Profile
A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms AxiGII
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Sep 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2017.